Effect of therapeutic intensification followed by HIV DNA prime and rAd5 boost vaccination on HIV-specific immunity and HIV reservoir (EraMune 02): A multicentre randomised clinical trial

The Lancet HIV

Volumn 2, Issue 3, 2015, Pages e82-e91

  Achenbach, Chad J ^a   Assoumou, Lambert ^b,c   Deeks, Steven G ^d   Wilkin, Timothy J ^e   Berzins, Baiba ^a   Casazza, Joseph P ^f   Lambert Niclot, Sidonie ^b,c,g   Koup, Richard A ^f   Costagliola, Dominique ^b,c   Calvez, Vincent ^b,c,g   Katlama, Christine ^b,c,g   Autran, Brigitte ^b,c,g   Murphy, Robert L ^a   Murphy, Robert ^a   Halverson, Amy ^a   Lambert, Nina ^a   Yip, Byron ^a   Rathert, Meredith ^a   Stroberg, Todd ^h   Hoh, Rebecca ⁱ   Kerbleski, Marian ⁱ   more..

^a NORTHWESTERN UNIVERSITY   (United States)

^b INSERM   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

^f NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^g PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^h Department of Obstetrics Gynecology   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE KINASE; CREATININE; DARUNAVIR; GAG PROTEIN; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 2; MARAVIROC; NEF PROTEIN; POL PROTEIN; RALTEGRAVIR; RECOMBINANT ADENOVIRUS 5 VACCINE; RITONAVIR; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS ENVELOPE PROTEIN; VIRUS RNA; VRC HIVADV014 00 VP; VRC HIVDNA016 00 VP; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DNA VACCINE;

ACUTE CORONARY SYNDROME; ACUTE KIDNEY FAILURE; ADAPTIVE IMMUNITY; ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DNA DETERMINATION; DRUG DOSE INTENSIFICATION; FOLLOW UP; GLOMERULONEPHRITIS; HEMODIALYSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN TISSUE; INJECTION SITE REACTION; INJECTION SITE SWELLING; KIDNEY BIOPSY; KIDNEY TUBULE DISORDER; KIDNEY TUBULE NECROSIS; LOCAL SKIN REACTION; LOW DRUG DOSE; MALAISE; MALE; MULTICENTER STUDY; MYALGIA; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN REDNESS; TREATMENT OUTCOME; ADENOVIRIDAE; ADOLESCENT; AGED; CLINICAL TRIAL; FEMALE; GENETICS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; MIDDLE AGED; MONONUCLEAR CELL; SECONDARY IMMUNIZATION; VACCINATION; VIROLOGY; VIRUS LOAD; YOUNG ADULT;

ADENOVIRIDAE; ADOLESCENT; ADULT; AGED; AIDS VACCINES; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; IMMUNIZATION, SECONDARY; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; TREATMENT OUTCOME; VACCINATION; VACCINES, DNA; VIRAL LOAD; YOUNG ADULT;

EID: 84925381938     PISSN: None     EISSN: 23523018     Source Type: Journal    
DOI: 10.1016/S2352-3018(15)00026-0     Document Type: Article

References (51)

1. Buzón MJ, Massanella M, Llibre JM, et al. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med 2010, 16:460-465.
2. Hatano H, Strain MC, Scherzer R, et al. Increase in 2-long terminal repeat circles and decrease in D-dimer after raltegravir intensification in patients with treated HIV infection: a randomized, placebo-controlled trial. J Infect Dis 2013, 208:1436-1442.
3. Shete A, Thakar M, Singh DP, et al. Short communication: HIV antigen-specific reactivation of HIV infection from cellular reservoirs: implications in the settings of therapeutic vaccinations. AIDS Res Hum Retroviruses 2012, 28:835-843.
4. Renga B, Francisci D, D'Amore C, et al. The HIV matrix protein p17 subverts nuclear receptors expression and induces a STAT1-dependent proinflammatory phenotype In monocytes. PLoS One 2012, 7:e35924.
5. Patterson LJ, Kuate S, Daltabuit-Test M, et al. Replicating adenovirus-simian immunodeficiency virus (SIV) vectors efficiently prime SIV-specific systemic and mucosal immune responses by targeting myeloid dendritic cells and persisting in rectal macrophages, regardless of immunization route. Clin Vaccine Immunol 2012, 19:629-637.
6. D'Souza MP, Frahm N Adenovirus 5 serotype vector-specific immunity and HIV-1 infection: a tale of T cells and antibodies. AIDS 2010, 24:803-809.
7. Catanzaro AT, Koup RA, Roederer M, et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J Infect Dis 2006, 194:1638-1649.
8. Catanzaro AT, Roederer M, Koup RA, et al. Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine. Vaccine 2007, 25:4085-4092.
9. Casazza JP, Bowman KA, Adzaku S, et al. Therapeutic vaccination expands and improves the function of the HIV-specific memory T-cell repertoire. J Infect Dis 2013, 207:1829-1840.
10. Williams JP, Hurst J, Stöhr W, et al. HIV-1 DNA predicts disease progression and post-treatment virological control. eLife 2014, published online Sept 12. 10.7554/eLife.03821.
11. Avettand-Fenoel V, Prazuck T, Hocqueloux L, et al. HIV-DNA in rectal cells is well correlated with HIV-DNA in blood in different groups of patients, including long-term non-progressors. AIDS 2008, 22:1880-1882.
12. Avettand-Fenoel V, Chaix M-L, Blanche S, et al. LTR real-time PCR for HIV-1 DNA quantitation in blood cells for early diagnosis in infants born to seropositive mothers treated in HAART area (ANRS CO 01). J Med Virol 2009, 81:217-223.
13. Graham BS, Koup RA, Roederer M, et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine. J Infect Dis 2006, 194:1650-1660.
14. Geldmacher C, Metzler IS, Tovanabutra S, et al. Minor viral and host genetic polymorphisms can dramatically impact the biologic outcome of an epitope-specific CD8 T-cell response. Blood 2009, 114:1553-1562.
15. Sarwar UN, Costner P, Enama ME, et al. Safety and immunogenicity of DNA vaccines encoding ebolavirus and marburgvirus wild-type glycoproteins in a phase I clinical trial. J Infect Dis 2015, 211:549-557.
16. Rasmussen TA, Tolstrup M, Brinkmann CR, et al. Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial. Lancet HIV 2014, 1:e13-e21.
17. Henrich TJ, Hanhauser E, Marty FM, et al. Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: report of 2 cases. Ann Intern Med 2014, 161:319-327.
18. Pollard RB, Rockstroh JK, Pantaleo G, et al. Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4x: a phase 2 randomised, double-blind, placebo-controlled trial. Lancet Infect Dis 2014, 14:291-300.
19. Li JZ, Heisey A, Ahmed H, et al. Relationship of HIV reservoir characteristics with immune status and viral rebound kinetics in an HIV therapeutic vaccine study. AIDS 2014, 28:2649-2657.
20. Archin NM, Liberty AL, Kashuba AD, et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 2012, 487:482-485.
21. Elliott JH, Wightman F, Solomon A, et al. Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy. PLoS Pathog 2014, 10:e1004473.
22. Wei DG, Chiang V, Fyne E, et al. Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing. PLoS Pathog 2014, 10:e1004071.
23. Vandergeeten C, Fromentin R, DaFonseca S, et al. Interleukin-7 promotes HIV persistence during antiretroviral therapy. Blood 2013, 121:4321-4329.
24. Lévy Y, Sereti I, Tambussi G, et al. Effects of recombinant human interleukin 7 on T-cell recovery and thymic output in HIV-infected patients receiving antiretroviral therapy: results of a phase I/IIa randomized, placebo-controlled, multicenter study. Clin Infect Dis 2012, 55:291-300.
25. Dianzani F, Antonelli G, Aiuti F, et al. The number of HIV DNA-infected mononuclear cells is reduced under HAART plus recombinant IL-2. IRHAN Study Group. Antiviral Res 2000, 45:95-99.
26. Azzoni L, Foulkes AS, Papasavvas E, et al. Pegylated Interferon alfa-2a monotherapy results in suppression of HIV type 1 replication and decreased cell-associated HIV DNA integration. J Infect Dis 2013, 207:213-222.
27. Winckelmann AA, Munk-Petersen LV, Rasmussen TA, et al. Administration of a Toll-like receptor 9 agonist decreases the proviral reservoir in virologically suppressed HIV-infected patients. PLoS One 2013, 8:e62074.
28. Persaud D, Luzuriaga K, Ziemniak C, et al. Effect of therapeutic HIV recombinant poxvirus vaccines on the size of the resting CD4+ T-cell latent HIV reservoir. AIDS 2011, 25:2227-2234.
29. Tebas P, Stein D, Tang WW, et al. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med 2014, 370:901-910.
30. Routy JP, Tremblay CL, Angel JB, et al. Valproic acid in association with highly active antiretroviral therapy for reducing systemic HIV-1 reservoirs: results from a multicentre randomized clinical study. HIV Med 2012, 13:291-296.
31. Hatano H, Hayes TL, Dahl V, et al. A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response. J Infect Dis 2011, 203:960-968.
32. Chege D, Kovacs C, la Porte C, et al. Effect of raltegravir intensification on HIV proviral DNA in the blood and gut mucosa of men on long-term therapy: a randomized controlled trial. AIDS 2012, 26:167-174.
33. Yukl SA, Shergill AK, McQuaid K, et al. Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy. AIDS 2010, 24:2451-2460.
34. Byakwaga H, Kelly M, Purcell DFJ, et al. Intensification of antiretroviral therapy with raltegravir or addition of hyperimmune bovine colostrum in HIV-infected patients with suboptimal CD4+ T-cell response: a randomized controlled trial. J Infect Dis 2011, 204:1532-1540.
35. Gandhi RT, Coombs RW, Chan ES, et al. No effect of raltegravir intensification on viral replication markers in the blood of HIV-1-infected patients receiving antiretroviral therapy. J Acquir Immune Defic Syndr 2012, 59:229-235.
36. Gandhi RT, Zheng L, Bosch RJ, et al. The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. PLoS Med 2010, 7:e1000321.
37. McMahon D, Jones J, Wiegand A, et al. Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy. Clin Infect Dis 2010, 50:912-919.
38. Besson GJ, McMahon D, Maldarelli F, Mellors JW Short-course raltegravir intensification does not increase 2 long terminal repeat episomal HIV-1 DNA in patients on effective antiretroviral therapy. Clin Infect Dis 2012, 54:451-453.
39. + T-cell recovery despite sustained virologic suppression: ACTG A5256. J Infect Dis 2012, 206:534-542.
40. Hunt PW, Shulman NS, Hayes TL, et al. The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4+ T-cell recovery: a randomized trial. Blood 2013, 121:4635-4646.
41. Dahl V, Lee E, Peterson J, et al. Raltegravir treatment intensification does not alter cerebrospinal fluid HIV-1 infection or immunoactivation in subjects on suppressive therapy. J Infect Dis 2011, 204:1936-1945.
42. Negredo E, Massanella M, Puertas MC, et al. Early but limited effects of raltegravir intensification on CD4 T cell reconstitution in HIV-infected patients with an immunodiscordant response to antiretroviral therapy. J Antimicrob Chemother 2013, 68:2358-2362.
43. Gutiérrez C, Díaz L, Vallejo A, et al. Intensification of antiretroviral therapy with a CCR5 antagonist in patients with chronic HIV-1 infection: effect on T cells latently infected. PLoS One 2011, 6:e27864.
44. Cuzin L, Trabelsi S, Delobel P, et al. Maraviroc intensification of stable antiviral therapy in HIV-1-infected patients with poor immune restoration: MARIMUNO-ANRS 145 study. J Acquir Immune Defic Syndr 2012, 61:557-564.
45. Vallejo A, Gutiérrez C, Hernández-Novoa B, et al. The effect of intensification with raltegravir on the HIV-1 reservoir of latently infected memory CD4 T cells in suppressed patients. AIDS 2012, 26:1885-1894.
46. Kawana-Tachikawa A, Llibre JM, Bravo I, et al. Effect of maraviroc intensification on HIV-1-specific T cell immunity in recently HIV-1-infected individuals. PLoS One 2014, 9:e87334.
47. Massanella M, Negredo E, Puig J, et al. Raltegravir intensification shows differing effects on CD8 and CD4 T cells in HIV-infected HAART-suppressed individuals with poor CD4 T-cell recovery. AIDS 2012, 26:2285-2293.
48. Rusconi S, Vitiello P, Adorni F, et al. Maraviroc as intensification strategy in HIV-1 positive patients with deficient immunological response: an Italian randomized clinical trial. PLoS One 2013, 8:e80157.
49. Eriksson S, Graf EH, Dahl V, et al. Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies. PLoS Pathog 2013, 9:e1003174.
50. Ho Y-C, Shan L, Hosmane NN, et al. Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell 2013, 155:540-551.
51. Pogliaghi M, Lambert S, Assoumou L, Zoorob R, Pagano L. HIV reservoir changes in resting CD4 subsets in the IL7 plus ART intensification EraMune 01 study. Conference on Retroviruses and Opportunistic Infections 2014; Boston, MA, USA, March 3-6, 2014. Abstract 424.